Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial

Podobne zapisy

• Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial
  od: Harrison, C, i wsp.
  Wydane: (2016)
• Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
  od: Greenfield, G, i wsp.
  Wydane: (2020)
• Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thrombocythemia
  od: Harrison, C, i wsp.
  Wydane: (2016)
• P989: DYNAMIC CHANGES IN THE HISTONE H3 LYSINE 27 TRIMETHYLATION EPIGENETIC LANDSCAPE FOLLOWING RUXOLITINIB ADMINISTRATION
  od: G. Greenfield, i wsp.
  Wydane: (2022-06-01)
• The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
  od: Graeme Greenfield, i wsp.
  Wydane: (2018-12-01)